PainReform Ltd. (Nasdaq: PRFX) — FY 2023 Form 20-F
Entity and period: The filing is for PainReform Ltd., an Israeli clinical-stage pharmaceutical company, for the fiscal year ended December 31, 2023—not a standalone Q4 report. The request metadata names PRF Technologies Ltd.; that name does not match the registrant in the filing. Financial statements are prepared under U.S. GAAP and reported in U.S. dollars.
Business context
PainReform is developing PRF-110, an extended-release formulation of ropivacaine intended to provide up to 72 hours of post-operative pain relief and reduce opioid use. The company has no approved products and has never generated revenue. Its U.S. Phase 3 bunionectomy trial resumed enrollment in October 2023 after an FDA-related delay involving the API supplier’s Drug Master File was resolved. A second Phase 3 trial for hernia repair is planned, contingent on successful completion of the first trial.
Key financial metrics
| Metric (US$ millions unless stated) | 2023 | 2022 | Change / context |
|---|---|---|---|
| Revenue | None | None | No product sales or other revenue reported. |
| Research and development expense | 6.035 | 4.422 | Up 36.4%, mainly from clinical-trial and manufacturing costs. |
| General and administrative expense | 3.549 | 4.447 | Down 18.2%, primarily from lower insurance and professional-services costs. |
| Operating loss | 9.584 | 8.869 | Widened as R&D spending increased. |
| Net loss | 9.344 | 8.792 | Loss widened 5.7%; 2023 included warrant-related gains and charges. |
| Net loss per share | $7.14 | $8.13 | Basic and diluted; share data reflect the 1-for-10 reverse split. |
| Net cash used in operating activities | 6.679 | 6.459 | Cash burn increased slightly. |
| Cash, cash equivalents and restricted cash at year-end | 8.036 | 4.106 | 2022 also included a $6.085 million short-term deposit; the deposit balance was zero in 2023. |
| Working capital | 7.4 | Not stated here | Positive at year-end 2023. |
| Accumulated deficit | 41.863 | 32.519 | Increased with continued losses. |
Margins are not meaningful because the company reported no revenue. No borrowings or debt securities are reported; year-end liabilities were $2.691 million, including $2.410 million current liabilities. Total assets were $9.930 million and shareholders’ equity was $7.239 million. The auditor issued an unmodified opinion on the financial statements but included a going-concern explanatory paragraph.
Material changes and financing
- R&D expense rose as the company progressed into Phase 3 and manufacturing activity; clinical-trial expense was $4.262 million in 2023 versus $1.121 million in 2022.
- 2023 financing activities generated $4.616 million net cash. Two July registered direct offerings and related warrant placements generated approximately $4.2 million gross proceeds; a December warrant-inducement transaction generated approximately $1.3 million gross proceeds at a reduced exercise price. The company reported total 2023 gross proceeds of $5.6 million and net proceeds of $4.6 million.
- The December transaction included new warrants for up to 935,792 shares at $2.85 per share. The filing also reports shares paid for but not yet issued at year-end, and warrants subject to beneficial-ownership limits; review the detailed transaction terms and dilution implications.
- The company effected a 1-for-10 reverse share split in June 2023. There were 1,728,347 ordinary shares outstanding at December 31, 2023.
Outlook, risks and unusual items
- Liquidity and going concern: Management estimated that available resources would fund operations only through the end of Q3 2024 and said additional capital would be needed to complete the clinical trial. The auditor cited substantial doubt about the company’s ability to continue as a going concern. Management’s financing plans include equity, debt or strategic partnerships, with no assurance funding will be available.
- Clinical and manufacturing execution: PRF-110’s pivotal-trial success, regulatory approval, market acceptance and future commercialization remain uncertain. The company has experienced manufacturing delays and relies on third parties, including a single supplier for some critical materials. A second Phase 3 trial is planned but not assured.
- Trial commitments: The contractual-obligations table lists $9.183 million due within one year under clinical research and trial agreements. Separately, the notes describe updated Lotus agreement payments of $15.8 million in total. Reconcile the scope, remaining payments and timing of these amounts.
- Warrant accounting: 2023 financial income included a $1.726 million gain from revaluing derivative warrant liabilities; the inducement transaction generated a $1.502 million loss. These non-operating items affected reported net loss.
- Israel and market risks: The company reported no material operational impact from the Israel-Hamas war as of the filing, but duration or regional expansion could disrupt personnel, operations or financing. It also cited capital-market volatility related to geopolitical conflicts and currency exposure to the NIS and euro.
- Controls and cybersecurity: Management concluded disclosure controls and internal control over financial reporting were effective at year-end 2023; the auditor did not provide an internal-control attestation. A 2022 vendor-impersonation incident caused a $165,000 transfer, most of which was recovered; management said the related material weakness had been remediated.
- Listing and governance: Nasdaq minimum-bid-price compliance was regained in July 2023. The company relies on certain foreign-private-issuer and home-country governance practices, which may provide different investor protections than U.S. domestic issuer rules.
Most important facts for investors to verify
- Current cash runway and subsequent financing, including the actual remaining cash available after year-end and the impact of warrant exercises or new issuances.
- Latest enrollment, completion timing, efficacy and safety results for the bunionectomy Phase 3 trial, plus the status and funding plan for the proposed hernia-repair trial.
- Reconciliation of the $9.183 million contractual-obligations disclosure with the $15.8 million total described for the Lotus agreements, including amounts already paid or accrued.
- Potential dilution from outstanding warrants, pre-funded warrants, unissued shares from the December exercise and share-based awards.
- Whether supplier capacity, manufacturing compliance and alternative sourcing are sufficient to avoid further clinical delays.
- Nasdaq continued-listing status, internal-control remediation evidence and any material developments affecting operations in Israel.